Thus, it appears that the concentration and activity of LCAT increases with obesity and obesity-associated low-grade inflammation, suggesting a compensatory mechanism, but appears to decrease when it comes to severe comorbidities and pathological conditions [35,47,48,49]. Here, LCAT is linked to obesity due to melanocortin 4 receptor deficiency.